181 related articles for article (PubMed ID: 26081291)
1. Novel thiourea-based sirtuin inhibitory warheads.
Zang W; Hao Y; Wang Z; Zheng W
Bioorg Med Chem Lett; 2015 Aug; 25(16):3319-24. PubMed ID: 26081291
[TBL] [Abstract][Full Text] [Related]
2. A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring N
Li R; Yan L; Sun X; Zheng W
Bioorg Med Chem; 2020 Apr; 28(7):115356. PubMed ID: 32067892
[TBL] [Abstract][Full Text] [Related]
3. Cyclic peptide-based potent and selective SIRT1/2 dual inhibitors harboring N
Chen D; Zheng W
Bioorg Med Chem Lett; 2016 Nov; 26(21):5234-5239. PubMed ID: 27707605
[TBL] [Abstract][Full Text] [Related]
4. Novel sirtuin inhibitory warheads derived from the N(ε)-acetyl-lysine analog L-2-amino-7-carboxamidoheptanoic acid.
He Y; Yan L; Zang W; Zheng W
Org Biomol Chem; 2015 Nov; 13(42):10442-50. PubMed ID: 26418815
[TBL] [Abstract][Full Text] [Related]
5. A Selective Cyclic Peptidic Human SIRT5 Inhibitor.
Liu J; Huang Y; Zheng W
Molecules; 2016 Sep; 21(9):. PubMed ID: 27626398
[TBL] [Abstract][Full Text] [Related]
6. A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK).
Hirsch BM; Hao Y; Li X; Wesdemiotis C; Wang Z; Zheng W
Bioorg Med Chem Lett; 2011 Aug; 21(16):4753-7. PubMed ID: 21752644
[TBL] [Abstract][Full Text] [Related]
7. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E
Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764
[TBL] [Abstract][Full Text] [Related]
8. Bivalent SIRT1 inhibitors.
Wang J; Zang W; Liu J; Zheng W
Bioorg Med Chem Lett; 2017 Jan; 27(2):180-186. PubMed ID: 27964881
[TBL] [Abstract][Full Text] [Related]
9. Human SIRT3 tripeptidic inhibitors containing N(ε)-thioacetyl-lysine.
Chen B; Wang J; Huang Y; Zheng W
Bioorg Med Chem Lett; 2015 Sep; 25(17):3481-7. PubMed ID: 26220157
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of 8-Mercapto-3,7-Dihydro-1
Han H; Li C; Li M; Yang L; Zhao S; Wang Z; Liu H; Liu D
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549218
[TBL] [Abstract][Full Text] [Related]
11. Cyclic Tripeptide-based Potent and Selective Human SIRT5 Inhibitors.
Jiang Y; Zheng W
Med Chem; 2020; 16(3):358-367. PubMed ID: 31161996
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new human Sirtuin 5 inhibitors by mimicking glutaryl-lysine substrates.
Yang F; Su H; Deng J; Mou L; Wang H; Li R; Dai QQ; Yan YH; Qian S; Wang Z; Li GB; Yang L
Eur J Med Chem; 2021 Dec; 225():113803. PubMed ID: 34461505
[TBL] [Abstract][Full Text] [Related]
13. Simple N(ε)-thioacetyl-lysine-containing cyclic peptides exhibiting highly potent sirtuin inhibition.
Huang Y; Liu J; Yan L; Zheng W
Bioorg Med Chem Lett; 2016 Mar; 26(6):1612-1617. PubMed ID: 26874402
[TBL] [Abstract][Full Text] [Related]
14. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
Farooqi AS; Hong JY; Cao J; Lu X; Price IR; Zhao Q; Kosciuk T; Yang M; Bai JJ; Lin H
J Med Chem; 2019 Apr; 62(8):4131-4141. PubMed ID: 30986062
[TBL] [Abstract][Full Text] [Related]
15. 3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).
Choi SH; Quinti L; Kazantsev AG; Silverman RB
Bioorg Med Chem Lett; 2012 Apr; 22(8):2789-93. PubMed ID: 22446090
[TBL] [Abstract][Full Text] [Related]
16. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.
Grbesa I; Pajares MJ; Martínez-Terroba E; Agorreta J; Mikecin AM; Larráyoz M; Idoate MA; Gall-Troselj K; Pio R; Montuenga LM
PLoS One; 2015; 10(4):e0124670. PubMed ID: 25915617
[TBL] [Abstract][Full Text] [Related]
17. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
20. Substrate specificity of SIRT1-catalyzed lysine Nepsilon-deacetylation reaction probed with the side chain modified Nepsilon-acetyl-lysine analogs.
Jamonnak N; Hirsch BM; Pang Y; Zheng W
Bioorg Chem; 2010 Feb; 38(1):17-25. PubMed ID: 19914676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
